Commercial Readiness with ImmunityBio's Bobby Reddy, M.D.

Business Of Biotech

We love to hear from our listeners. Send us a message.

This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team at ImmunityBio are doing to change that standard of care. They're painfully close. Dr. Reddy, Chief Medical Officer at ImmunityBio, gives us a long look behind the curtain at the commercial preparations the company is making as its lead Phase 3 candidate, Anktiva, nears the goal line in non-muscle invasive bladder cancer (NMIBC). From grassroots engagement with physicians and urologists to making a global press to share clinical results, Dr. Reddy offers plenty of insight into biopharma commercial readiness, and good reason to hope for nearly a million NMIBC patients in the U.S. alone.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Bab

1. Innovative Cancer Treatment Breakthrough (00:00:00)

2. Advancing Cancer Treatments (00:10:26)

3. Navigating Drug Development and Clinical Trials (00:23:36)

4. Shifting to Commercialization Efforts in Biopharma (00:34:12)

5. Bladder Cancer Treatment Costs and Manufacturing (00:39:53)

6. Immunity Bio's Comprehensive Biopharmaceutical Strategy (00:44:23)